The Plasma-SeqSensei™ (PSS) Thyroid Cancer RUO (research use only) Kit detects mutations in circulating tumour DNA (ctDNA) from plasma in patients with thyroid cancer.
The kit uses next generation sequencing and covers the BRAF and NRAS genes with hotspot mutations:. These gene mutations are associated with more rapid cancer growth and worse prognosis. [1-2]
Differentiated (papillary (PTC) and follicular TC (FTC)) make up more than 90% of thyroid malignancies (BRAF with >60% and NRAS with 6-57% frequency of known somatic mutations). 
For the configuration of the Plasma-SeqSensei™ Thyroid RUO kits, two key cancer genes were selected after comparison of mutation frequencies using the COSMIC (Catalogue of Somatic Mutation in Cancer) and cBioPortal for cancer genomics databases.